Integrin αL/ITGAL/CD11a Antibody (HI111): sc-19647

Integrin αL Antibody (HI111) is a mouse monoclonal IgG1 antibody that detects Integrin αL in human samples through applications such as immunofluorescence (IF) and flow cytometry (FCM). Integrin αL, also called CD11a, is a crucial component of the immune system, primarily expressed on leukocytes, where anti-Integrin αL antibody (HI111) plays a vital role in mediating cell adhesion and migration. Integrin αL is essential for the immune response, facilitating interaction between leukocytes and endothelial cells during inflammation, allowing immune cells to exit the bloodstream and reach sites of infection or injury. The structure of Integrin αL, consisting of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail, enables conformational changes necessary for activation and function. These structural features allow Integrin αL to bind to ligands, such as intercellular adhesion molecules (ICAMs), effectively promoting leukocyte adhesion and migration. The ability of Integrin αL to interact with various ligands is critical for maintaining immune surveillance and responding to pathological conditions, making Integrin αL a key target for therapeutic interventions in inflammatory diseases and cancer. Integrin αL monoclonal antibody (HI111) serves as an invaluable tool for researchers studying these processes and the underlying mechanisms of immune cell behavior.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Integrin αL/ITGAL/CD11a Antibody (HI111) References:

1. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins.  |  Ihanus, E., et al. 2003. Eur J Biochem. 270: 1710-23. PMID: 12694184
2. Mean fluorescence intensity (MFI) of beta2 integrin (CD11a and CD11b) expression on peripheral blood (PB) CD34-positive (CD34(+)) cells in steady state correlates inversely with the total amount of harvested CD34(+) cells.  |  Masauzi, N., et al. 2003. Bone Marrow Transplant. 31: 1069-70. PMID: 12774064
3. Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity.  |  Jansen, JH., et al. 1992. Blood. 80: 478-83. PMID: 1352710
4. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.  |  Krueger, JG., et al. 2008. J Invest Dermatol. 128: 2615-2624. PMID: 18496564
5. Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab.  |  Kuschei, WM., et al. 2011. Clin Immunol. 139: 199-207. PMID: 21414849
6. Upregulation of CD11A on hematopoietic stem cells denotes the loss of long-term reconstitution potential.  |  Fathman, JW., et al. 2014. Stem Cell Reports. 3: 707-15. PMID: 25418718
7. Two leukocyte receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands.  |  Lo, SK., et al. 1989. J Immunol. 143: 3325-9. PMID: 2809204
8. The human leukocyte integrin CD11a promoter directs expression in leukocytes of transgenic mice.  |  Ritchie, KA., et al. 1995. Blood. 86: 147-55. PMID: 7795220
9. Role of CD11a and CD11b in ischemic acute renal failure in rats.  |  Rabb, H., et al. 1994. Am J Physiol. 267: F1052-8. PMID: 7810691
10. Description of the leukocyte function-associated antigen 1 (LFA-1 or CD11a) promoter.  |  Cornwell, RD., et al. 1993. Proc Natl Acad Sci U S A. 90: 4221-5. PMID: 8097887

The preferred Integrin αL/ITGAL/CD11a antibody is Integrin αL/ITGAL/CD11a Antibody (E-1): sc-374172.